Additionally, because the clinical immunoassays used did not provide paired measurements of the corresponding non‐phosphorylated or total tau peptides, we were unable to compute p‐tau/total‐tau ratios, which have been previously shown to mitigate the impact of chronic kidney disease (CKD) on p‐tau increases.25 This evidence concerns the gene MAPT and chronic kidney disease.